ctDNA-based next-generation sequencing in 236 patients with advanced breast cancer revealed frequent PIK3CA, TP53, and ESR1 mutations, highlighting key mechanisms of endocrine resistance with implications for targeted therapy selection.
Marcela Mazo Canola
Advertisement
Articles by Marcela Mazo Canola
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Risvutatug Rezetecan Improves Overall Survival in Relapsed SCLC Trial
2
Dostarlimab Yields Sustained Complete Responses in dMMR/MSI-H Rectal Cancer
3
FDA Accepts NDA for Mezigdomide Combo in R/R Multiple Myeloma
4
FDA Rejects Rivoceranib/Camrelizumab in First-Line Unresectable HCC
5